The trial of the company’s metastatic pancreatic cancer treatment, elraglusib, similarly saw the one-year survival rate reach ...

Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year ...

Shares of Actuate Therapeutics on Tuesday climbed after the company said that it received positive data from its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel to treat ...

Marker Therapeutics (NASDAQ:MRKR) shares popped 11% Tuesday morning after the immuno-oncology company won a $9.5M grant from ...

Pancreatic cancer can be a silent killer -- the organ is located deep inside the body, making cancer harder to detect before ...

Dec. 12, 2024 — Researchers have successfully developed a deep learning model that classifies pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, into molecular ...

Pulmonary metastases occur also very often in sarcoma, a relatively rare type of cancer. As many as 20% of soft tissue sarcomas and up to 40% of bone sarcomas develop lung metastases. Occasionally, ...

Breast, bladder, and pancreatic cancers are increasingly being treated with a broad range of therapies before a patient ...

Caregivers are crucial in the pancreatic cancer patient’s journey. We have information and resources to guide you as you care for a loved one facing the disease.

IMM-1-104 is a small molecule commercialized by Immuneering, with a leading Phase II program in Pancreatic Cancer.

Researchers have successfully developed a deep learning model that classifies pancreatic ductal adenocarcinoma (PDAC), the most common form of ...

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® ARTEMIA: Clinical trial protocol ...